Biomarin Pharmaceutical Inc (BMRN)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 79.61% | 78.31% | 76.62% | 74.33% | 71.24% |
| Operating profit margin | 17.02% | 7.82% | 7.23% | -4.49% | -2.38% |
| Pretax margin | 19.04% | 7.94% | 7.23% | -4.11% | -2.69% |
| Net profit margin | 15.00% | 7.06% | 6.84% | -3.50% | 46.84% |
Biomarin Pharmaceutical Inc's gross profit margin has shown a consistent upward trend over the years, increasing from 71.24% in 2020 to 79.61% in 2024. This indicates the company's ability to control production costs and generate higher profits from its revenue.
However, the operating profit margin started in the negative territory in 2020 and 2021 but improved significantly in the following years, reaching 17.02% in 2024. This shows that the company has been able to better manage its operating expenses and become more efficient in its operations.
Similarly, the pretax margin has also shown a positive trend, increasing from -2.69% in 2020 to 19.04% in 2024. This demonstrates Biomarin Pharmaceutical Inc's ability to generate higher profits before accounting for taxes, reflecting improved operational performance and cost management.
Lastly, the net profit margin, which indicates the company's bottom-line profitability, improved from a negative margin in 2021 to 15.00% in 2024. This suggests that the company has been successful in controlling its costs and increasing its net income relative to its total revenue, resulting in a healthier bottom line.
Overall, Biomarin Pharmaceutical Inc has shown strong improvements in its profitability ratios over the years, indicating efficient cost management and improved operational performance, leading to higher profitability levels.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 6.93% | 2.72% | 2.35% | -1.37% | -0.74% |
| Return on assets (ROA) | 6.11% | 2.45% | 2.22% | -1.07% | 14.60% |
| Return on total capital | 7.74% | 3.71% | 2.91% | -1.12% | -0.38% |
| Return on equity (ROE) | 7.54% | 3.39% | 3.08% | -1.50% | 20.83% |
Based on the provided data for Biomarin Pharmaceutical Inc, the company's profitability ratios show fluctuations over the years.
1. Operating return on assets (Operating ROA) has been negative at the end of 2020 and 2021, indicating that the company's operating income generated from its assets was insufficient to cover the assets' costs. However, there was an improvement towards positive figures in 2022, 2023, and 2024, reaching 2.35%, 2.72%, and 6.93%, respectively.
2. Return on assets (ROA) was strong at the end of 2020 with 14.60%, indicating that the company generated a significant return from its total assets. However, there was a decline in 2021 with a negative figure, followed by a recovery in 2022, 2023, and 2024 at 2.22%, 2.45%, and 6.11%, respectively.
3. Return on total capital also showed negative returns at the end of 2020 and 2021, suggesting that the company's return on the total capital invested was insufficient. However, there was an improvement in 2022, 2023, and 2024, reaching 2.91%, 3.71%, and 7.74%, respectively.
4. Return on equity (ROE) was positive at the end of 2020, indicating that the company generated a return for its shareholders. However, this metric turned negative in 2021 but gradually improved in 2022, 2023, and 2024 to 3.08%, 3.39%, and 7.54%, respectively.
Overall, Biomarin Pharmaceutical Inc's profitability ratios show a mix of positive and negative trends, with improvements in the later years indicating better utilization of assets and capital to generate returns and enhance shareholder value.